[PDF][PDF] Combined point-of-care nucleic acid and antibody testing for SARS-CoV-2 following emergence of D614G spike variant

…, H Knock, R Hardy, E Foster, F Davidson, V Rundell… - Cell Reports …, 2020 - cell.com
Rapid COVID-19 diagnosis in the hospital is essential, although this is complicated by 30%–50%
of nose/throat swabs being negative by SARS-CoV-2 nucleic acid amplification testing (…

[PDF][PDF] Point of care nucleic acid testing for SARS-CoV-2 in hospitalized patients: a clinical validation trial and implementation study

…, H Knock, R Hardy, E Foster, F Davidson, V Rundell… - Cell Reports …, 2020 - cell.com
There is an urgent need for rapid SARS-CoV-2 testing in hospitals to limit nosocomial spread.
We report an evaluation of point of care (POC) nucleic acid amplification testing (NAAT) in …

Stroke survivors' and informal caregivers' experiences of primary care and community healthcare services–a systematic review and meta-ethnography

DM Pindus, R Mullis, L Lim, I Wellwood, AV Rundell… - PloS one, 2018 - journals.plos.org
Objective To describe and explain stroke survivors and informal caregivers’ experiences of
primary care and community healthcare services. To offer potential solutions for how …

Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.

…, M Perry, G Marsico, A Ruiz-Valdepeñas, V Rundell… - 2021 - ascopubs.org
8517 Background: Liquid biopsies based on circulating tumor DNA (ctDNA) analysis are
being investigated for detection of residual disease and recurrence. Conclusive evidence for …

[PDF][PDF] Sensitive detection of ctDNA in early-stage non-small cell lung cancer patients with a personalized sequencing assay

…, P Ellis, R Osborne, K Howarth, T Lazarus, V Rundell… - Cancer, 2020 - neogenomics.com
▪ Stage IA-IIIB NSCLC patients were recruited to the LUCID study. 90 patients undergoing
radical treatment with curative intent, either surgery (n= 70) or radiotherapy (RT)±…

Detection of residual disease and recurrence in early-stage non-small cell lung cancer (NSCLC) patients using sensitive personalized ctDNA sequencing assays.

…, G Sharma, M Perry, R Osborne, K Howarth, V Rundell… - 2020 - ascopubs.org
e15560 Background: Detection of residual circulating tumour DNA (ctDNA) in patient plasma
following curative intervention for localized non-small cell lung cancer (NSCLC) could …

ctDNA detection by personalised assays in early-stage NSCLC

…, J Wulff, K Howarth, E Green, J Castedo, V Rundell… - MedRxiv, 2021 - medrxiv.org
Blood-based assays have shown increasing ability to detect circulating tumour DNA (ctDNA)
in patients with early-stage cancer. However, detection of ctDNA in patients with non-small …

Primary care interventions and current service innovations in modifying long-term outcomes after stroke: a protocol for a scoping review

DM Pindus, L Lim, AV Rundell, V Hobbs, N Abd Aziz… - BMJ open, 2016 - bmjopen.bmj.com
Introduction Interventions delivered by primary and/or community care have the potential to
reach the majority of stroke survivors and carers and offer ongoing support. However, an …

[PDF][PDF] ctDNA detection in early-stage non-small cell lung cancer

…, N Demiris, K Howarth, E Green, V Rundell… - Cancer …, 2020 - neogenomics.com
… Katrin Heider1,2, Jonathan CM Wan1,2, Davina Gale1,2, Andrea Ruiz-Valdepenas1,2,
Florent Mouliere1,2,3, James Morris1,2, Wendi Qian4, Jerome Wulff4, Nikolaos Demiris4 …

Correction: Stroke survivors' and informal caregivers' experiences of primary care and community healthcare services-A systematic review and meta-ethnography

DM Pindus, R Mullis, L Lim, I Wellwood, AV Rundell… - Plos one, 2018 - journals.plos.org
1. Pindus DM, Mullis R, Lim L, Wellwood I, Rundell AV, Abd Aziz NA, et al.(2018) Stroke
survivors’ and informal caregivers’ experiences of primary care and community healthcare …